- Home
- ACB vs MRVI Comparison
ACB vs MRVI Comparison
Compare ACB & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACB
- MRVI
- Stock Information
- Founded
- ACB 2013
- MRVI 2014
- Country
- ACB Canada
- MRVI United States
- Employees
- ACB N/A
- MRVI N/A
- Industry
- ACB Pharmaceuticals and Biotechnology
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- ACB Health Care
- MRVI Health Care
- Exchange
- ACB Nasdaq
- MRVI Nasdaq
- Market Cap
- ACB 313.9M
- MRVI 312.4M
- IPO Year
- ACB N/A
- MRVI 2020
- Fundamental
- Price
- ACB $4.31
- MRVI $2.51
- Analyst Decision
- ACB Hold
- MRVI Hold
- Analyst Count
- ACB 1
- MRVI 10
- Target Price
- ACB N/A
- MRVI $6.84
- AVG Volume (30 Days)
- ACB 1.6M
- MRVI 1.8M
- Earning Date
- ACB 06-18-2025
- MRVI 08-06-2025
- Dividend Yield
- ACB N/A
- MRVI N/A
- EPS Growth
- ACB N/A
- MRVI N/A
- EPS
- ACB 0.03
- MRVI N/A
- Revenue
- ACB $238,837,444.00
- MRVI $241,856,000.00
- Revenue This Year
- ACB $12.22
- MRVI N/A
- Revenue Next Year
- ACB $7.36
- MRVI $10.62
- P/E Ratio
- ACB $149.95
- MRVI N/A
- Revenue Growth
- ACB 27.32
- MRVI N/A
- 52 Week Low
- ACB $3.42
- MRVI $1.67
- 52 Week High
- ACB $7.20
- MRVI $10.03
- Technical
- Relative Strength Index (RSI)
- ACB 38.17
- MRVI 62.25
- Support Level
- ACB $3.91
- MRVI $2.00
- Resistance Level
- ACB $6.21
- MRVI $2.44
- Average True Range (ATR)
- ACB 0.28
- MRVI 0.15
- MACD
- ACB -0.14
- MRVI 0.04
- Stochastic Oscillator
- ACB 15.31
- MRVI 91.89
About ACB Aurora Cannabis Inc.
Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.